Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review

BACKGROUND: Based on several phase III studies, immune checkpoint inhibitors (ICIs) are essential and promising drugs for the treatment of non‐small cell lung cancer (NSCLC). However, in patients previously treated with ICI, the efficacy and safety of rechallenging the same or another type of ICI in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitagawa, Shingo, Hakozaki, Taiki, Kitadai, Rui, Hosomi, Yukio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327670/
https://www.ncbi.nlm.nih.gov/pubmed/32421224
http://dx.doi.org/10.1111/1759-7714.13483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327670/
https://www.ncbi.nlm.nih.gov/pubmed/32421224
http://dx.doi.org/10.1111/1759-7714.13483

Ejemplares similares